Citation Impact
Citing Papers
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
2013
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
2010
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA
2021 StandoutNobel
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
2021 StandoutNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
2012
mRNA therapeutics in cancer immunotherapy
2021
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
2015
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
2017
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia
2010
A view on drug resistance in cancer
2019 StandoutNature
Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate
2017
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
New treatment for acute myelogenous leukemia
2014
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
2023 StandoutNobel
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
2010
Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
2013
Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates
2020
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
2014
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Quantum dots as a platform for nanoparticle drug delivery vehicle design
2012
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The CDK inhibitors in cancer research and therapy
2011
Idarucizumab for Dabigatran Reversal
2015 Standout
Leukaemogenesis: more than mutant genes
2009
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
2006
AKT/PKB Signaling: Navigating the Network
2017 Standout
Therapy with azanucleosides for myelodysplastic syndromes
2010
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
The PI3K Pathway in Human Disease
2017 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
2018 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
2009
The cancer genome
2009 StandoutNature
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Philadelphia chromosome‐positive mixed phenotype acute leukemia in the imatinib era
2014
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
Histone Deacetylase Inhibitors as Anticancer Drugs
2017
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
Prognostic impact and targeting of CRM1 in acute myeloid leukemia
2013
Targeted and Equally Distributed Delivery of mRNA to Organs with Pentaerythritol-Based One-Component Ionizable Amphiphilic Janus Dendrimers
2023 StandoutNobel
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
Acute Myeloid Leukemia
2015 Standout
A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke
2010 Standout
2013
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
The Tumor Lysis Syndrome
2011 Standout
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
2012
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
2015
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Cytokine Storm
2020 Standout
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
2022 StandoutScienceNobel
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
2014
Chimeric Antigen Receptor Therapy
2018 Standout
How I treat refractory and early relapsed acute myeloid leukemia
2015
Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor
2012
Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers
2021 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
2008 Standout
Multiple Myeloma
2011 Standout
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
2007
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2010
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Works of William Blum being referenced
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
2010
Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
2008
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies
2009
Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants
2004
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
2008
Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: Consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity
2002
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23)
2004
Development and validation of a rapid and sensitive high-performance liquid chromatography–mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma
2008
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)
2013
Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells
2007
Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes
2004
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
2010
A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels
2009
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
2007
Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity
2005
Persistence of DNMT 3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
2016
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
2004
Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia
2017
Novel Therapies in AML: Reason for Hope or Just Hype?
2014
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
2007
RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans
2012
Targeting epigenetic changes in acute myeloid leukemia.
2005
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
2007
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)
2012
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): Results from Cancer and Leukemia Group B study 8461 and review of the literature
2005
Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.
2007
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
2008
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
2012
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia
2007